Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September
Processa Pharmaceuticals (Nasdaq: PCSA) has announced its participation in two major conferences this September. The company will attend the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York. Management will conduct one-on-one investor meetings and deliver a company presentation, which will be available on-demand from September 9th at 7:00 am Eastern time on Processa's website.
Additionally, Processa will participate in the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona from September 13-17, 2024. During this event, management will meet with clinicians, researchers, industry key opinion leaders, and potential partners. These conferences provide Processa with valuable opportunities to showcase their developments and network within the pharmaceutical and investment communities.
Processa Pharmaceuticals (Nasdaq: PCSA) ha annunciato la sua partecipazione a due importanti conferenze questo settembre. L'azienda parteciperà alla 26ª Conferenza Annuale Globale di Investimento H.C. Wainwright dal 9 all'11 settembre 2024, a New York. La direzione condurrà incontri individuali con gli investitori e presenterà un intervento aziendale, che sarà disponibile on-demand a partire dal 9 settembre alle 7:00 ora orientale sul sito web di Processa.
Inoltre, Processa parteciperà al Congresso 2024 della Società Europea di Oncologia Medica (ESMO) a Barcellona dal 13 al 17 settembre 2024. Durante questo evento, la direzione incontrerà clinici, ricercatori, leader d'opinione del settore e potenziali partner. Queste conferenze offrono a Processa preziose opportunità per mostrare i propri sviluppi e creare contatti all'interno delle comunità farmaceutiche e di investimento.
Processa Pharmaceuticals (Nasdaq: PCSA) ha anunciado su participación en dos conferencias importantes este septiembre. La empresa asistirá a la 26ª Conferencia Anual Global de Inversión H.C. Wainwright del 9 al 11 de septiembre de 2024, en Nueva York. La dirección llevará a cabo reuniones individuales con inversores y presentará una exposición de la compañía, que estará disponible bajo demanda a partir del 9 de septiembre a las 7:00 am, hora del este, en el sitio web de Processa.
Además, Processa participará en el Congreso 2024 de la Sociedad Europea de Oncología Médica (ESMO) en Barcelona del 13 al 17 de septiembre de 2024. Durante este evento, la dirección se reunirá con clínicos, investigadores, líderes de opinión clave de la industria y posibles socios. Estas conferencias ofrecen a Processa valiosas oportunidades para exhibir sus desarrollos y establecer redes dentro de las comunidades farmacéuticas y de inversión.
프로세사 제약 회사 (Nasdaq: PCSA)는 이번 9월 두 개의 주요 컨퍼런스에 참가한다고 발표했습니다. 이 회사는 2024년 9월 9일부터 11일까지 뉴욕에서 열리는 H.C. 웨인라이트 제26회 연례 글로벌 투자 컨퍼런스에 참석할 예정입니다. 경영진은 투자자와의 1:1 회의를 진행하고, 회사 발표를 진행할 것입니다. 이 발표는 9월 9일 오전 7시 동부 시간 기준으로 프로세사 웹사이트에서 온디맨드로 제공될 예정입니다.
또한, 프로세사는 2024년 9월 13일부터 17일까지 바르셀로나에서 열리는 유럽종양학회(ESMO) 총회 2024에도 참여할 예정입니다. 이 행사 동안 경영진은 임상의, 연구자, 업계 주요 의견 지도자 및 잠재적 파트너들과 만날 것입니다. 이러한 컨퍼런스는 프로세사에게 개발 내용을 보여주고 제약 및 투자 커뮤니티 내에서 네트워크를 형성할 수 있는 귀중한 기회를 제공합니다.
Processa Pharmaceuticals (Nasdaq: PCSA) a annoncé sa participation à deux grandes conférences ce septembre. L'entreprise assistera à la 26ème Conférence Annuelle Mondiale d'Investissement H.C. Wainwright du 9 au 11 septembre 2024, à New York. La direction organisera des réunions individuelles avec des investisseurs et présentera une exposé de l'entreprise, qui sera disponible à la demande à partir du 9 septembre à 7h00 heure de l'Est sur le site web de Processa.
De plus, Processa participera au Congrès 2024 de la Société Européenne d'Oncologie Médicale (ESMO) à Barcelone du 13 au 17 septembre 2024. Lors de cet événement, la direction rencontrera des cliniciens, des chercheurs, des leaders d'opinion clés de l'industrie et des partenaires potentiels. Ces conférences offrent à Processa de précieuses opportunités pour présenter ses développements et créer des liens au sein des communautés pharmaceutiques et d'investissement.
Processa Pharmaceuticals (Nasdaq: PCSA) hat seine Teilnahme an zwei wichtigen Konferenzen im September angekündigt. Das Unternehmen wird vom 9. bis 11. September 2024 an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright in New York teilnehmen. Das Management wird persönliche Investorenmeetings abhalten und eine Unternehmenspräsentation halten, die ab dem 9. September um 7:00 Uhr Eastern Time auf der Website von Processa on-demand verfügbar sein wird.
Darüber hinaus wird Processa am ESMO-Kongress 2024 der Europäischen Gesellschaft für medizinische Onkologie in Barcelona vom 13. bis 17. September 2024 teilnehmen. Während dieser Veranstaltung wird das Management mit Klinikern, Forschern, einflussreichen Vertretern der Branche und potenziellen Partnern zusammentreffen. Diese Konferenzen bieten Processa wertvolle Gelegenheiten, ihre Entwicklungen zu präsentieren und innerhalb der pharmazeutischen und Investmentgemeinschaften zu netzwerken.
- None.
- None.
HANOVER, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces that management will be participating in the following investor and industry conferences during the month of September:
- H.C. Wainwright 26th Annual Global Investment Conference, September 9-11, 2024, at the Lotte New York Palace Hotel. Management will be holding one-on-one meetings with investors and will deliver a company presentation. The recorded presentation will be available on demand beginning Monday, September 9th at 7:00am Eastern time on the Investors section of Processa’s website and here.
- European Society for Medical Oncology (ESMO) Congress 2024, September 13-17, 2024, in Barcelona. Management will be holding meetings with clinicians, researchers, industry key opinion leaders and potential partners.
About Processa Pharmaceuticals, Inc.
Processa is a clinical-stage pharmaceutical company focused on developing the Next Generation Chemotherapy (NGC) drugs with improved safety and efficacy. Processa’s NGC drugs are modifications of existing FDA-approved oncology therapies resulting in an alteration of the metabolism and/or distribution of these drugs while maintaining the existing mechanisms of killing the cancer cells. By combining its novel oncology pipeline with proven cancer-killing active molecules and its Regulatory Science Approach, Processa’s strategy is to develop more effective therapy options with improved tolerability for cancer patients through an efficient regulatory path.
For more information, visit our website at www.processapharma.com.
Company Contact:
Patrick Lin
(925) 683-3218
plin@processapharma.com
Investor Relations Contact:
Yvonne Briggs
LHA Investor Relations
(310) 691-7100
ybriggs@lhai.com
# # #
FAQ
Which conferences will Processa Pharmaceuticals (PCSA) attend in September 2024?
When and where will Processa Pharmaceuticals' (PCSA) company presentation be available for the H.C. Wainwright conference?
What activities will Processa Pharmaceuticals (PCSA) engage in during the ESMO Congress 2024?
Where is the H.C. Wainwright 26th Annual Global Investment Conference being held?
